Patients with oligodendroglioma are generally assumed to show a more favorable clinical course than those with IDH-mutant astrocytoma, which is reflected by the low fatality rate of 9 of 39 patients (23%) with oligodendroglioma versus 25 of 47 patients (53%) with astrocytoma in our dataset and substantiated by univariate analysis (Table 2) [8, 20, 21]. The gene discussed is IDH2; the disease is oligodendroglioma.